Promoters of Symbiotec Pharmalab have re-created an encumbrance over 66,92,638 equity shares, representing 10.45% of the company’s total share capital. The pledge was registered in favour of Beacon Trusteeship Limited on September 11, 2026.

The disclosure was made pursuant to Regulation 31(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Beacon Trusteeship Limited acted in its capacity as the debenture trustee for Satwani Holdings (India) Private Limited (SHIPL).

Pledge Re-Creation Context

The company stated that the pledge was originally created on December 10, 2025, by certain members of the promoter group pursuant to a Target Pledge Agreement. It was temporarily released solely to enable the creation of applicable lock-ins on pre-issue shareholding in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Upon completion of the lock-in process and the Initial Public Offer, the pledge has been re-created over the relevant equity shares. The company described this as an administrative process with effectively no change in the pledged holding.

Encumbrance Details

The encumbrance serves as security for non-convertible debentures issued by SHIPL. A debenture trust deed dated December 10, 2025, as amended on December 18, 2025, governs the transaction. Under the terms, Mr. Anil Satwani and Mrs. Kashish Satwani created a charge over 100% of their partnership interest in Satwani Holdings LLP.

Satwani Holdings LLP currently holds 98,19,885 equity shares of Symbiotec Pharmalab, constituting 15.28% of the share capital on a fully diluted basis.

Promoter Pledge Breakdown

Members of the promoter group created pledges over specific shareholdings between September 8 and September 10, 2026. The total pledged shares amount to 66,92,638.

Covenant Conditions

The debenture trust deed includes a covenant regarding promoter ownership levels. If the promoter group ceases to own at least 26% of the equity share capital or voting rights in the target group, free from encumbrance, the associated debt must be repaid.

The promoter group comprises Mr. Anil Satwani, Mrs. Kashish Satwani, Mr. Sushil Satwani, Satwani Holdings LLP, and three family trusts: Krishna Anil Satwani Family Trust, Arjun Anil Satwani Family Trust, and Kashish and Anil Satwani Family Trust.

Symbiotec Pharmalab Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to the Bombay Stock Exchange and National Stock Exchange on September 3, 2026.

The filing was made pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company stated that the code is framed under Regulation 8(1) of the same regulations.

Salil Jain, Company Secretary and Compliance Officer, signed the intimation letter addressed to the Listing Departments of both exchanges. The submission serves as an informational record for the exchanges.

Policy Effective Date

The policy shall come into effect on December 15, 2025. This retroactive effective date aligns the company’s internal compliance framework with prior regulatory expectations.

Fair Disclosure Principles

The code aims to preserve the confidentiality of unpublished price sensitive information (UPSI) and prevent its misuse. Key principles include:

• Promptly disclosing publicly any UPSI that would impact price discovery.
• Uniformly disseminating UPSI to avoid selective disclosure by communicating with stock exchanges and publishing on the company website.
• Disclosing press releases considered important for the general public.
• Publishing quarterly and annual financial results and investor presentations on the company website.
• Promptly disseminating UPSI disclosed selectively or inadvertently.
• Handling price sensitive information on a need-to-know basis.

Chief Investor Relations Officer

The Board of Directors has appointed a Chief Investor Relations Officer (CIRO), who reports to the Chief Financial Officer. The CIRO is responsible for compliance with the Fair Disclosure Code and handling dissemination of information. Employees are not authorized to respond to enquiries from stock exchanges or media unless approved by the CIRO or CFO.

Company Details

The registered office of Symbiotec Pharmalab Limited is located in Indore, Madhya Pradesh.